The ABCs Of Accelerated Approval Withdrawals
Executive Summary
At least six accelerated approval drugs have either been withdrawn or had indications revoked because confirmatory studies were not completed or failed to verify clinical benefit – including Avastin, Bexxar and Celebrex.
You may also be interested in...
Keeping Track: Bad News For Bristol And Lilly, Good News For TG Therapeutics
The latest drug development news and highlights from our US FDA Performance Tracker.
Product Withdrawal Can Be As Hard As Approval: Luveris' 4-Year Journey Ends
EMD Serono had not marketed the infertility treatment in US since 2012, when it first asked FDA to withdraw application; company was unable to complete confirmatory trial required under accelerated approval.
“Not Another Avastin,” FDA Panel Warns Genentech At Perjeta Review
Under questioning from FDA’s Richard Pazdur, VP Sandra Horning says company would be willing to withdraw pertuzumab’s neoadjuvant indication if results from ongoing adjuvant study are “clearly negative”; advisory committee members say they expect sponsor to bow out more gracefully than it did in the fight over bevacizumab’s breast cancer claim.